Moreover, in contrast with tumour tissue biopsies and cfDNA, it is noteworthy that only one CTC harboured a BRAFV600E mutation, which suggests that resistance to BRAF inhibitors may not be driven by BRAFV600E-mutated CTCs. Here, BRAF is linked to neoplasm.